Oncolytics Biotech (US:ONCY) Prnewswireยท2025-01-22 14:00Core Insights - The 2025 ASCO Gastrointestinal Cancers Symposium is set to highlight the alarming rise in cancer rates among individuals under 50, particularly gastrointestinal cancers, with colorectal and pancreatic cancers being significant concerns [1][2] - Oncolytics Biotech Inc. is presenting data on pelareorep, an innovative immunotherapy that aims to convert "cold" tumors into "hot" tumors, enhancing treatment response [3][4] Company Developments - In a study involving relapsed anal cancer, pelareorep achieved a 33% response rate, with one patient showing a complete response lasting over 15 months, significantly outperforming typical treatment response rates of 10-24% [4][5] - Pelareorep has shown strong potential in pancreatic cancer, with new safety data indicating its compatibility with modified FOLFIRINOX chemotherapy, expanding treatment options for metastatic pancreatic cancer [5][6] - The GOBLET study demonstrated a 62% objective response rate for pelareorep combined with other therapies, more than double the historical average of 25%, leading to its FDA Fast Track designation in 2022 [6][7] Industry Trends - The Global Pancreatic Cancer Treatment Market is projected to grow at a 7.6% CAGR, while the global stomach cancer treatment market is expected to reach $17.6 billion by 2034, growing at a 12.54% CAGR [2] - Other companies presenting at the ASCO GI symposium include Agenus Inc., which will showcase its immunotherapy treatments for colorectal cancer, and ALX Oncology, which is advancing therapies to enhance immune response against cancer [10][11][12]